Phenytoin kinetics in Japanese adult epileptics: Phenotype of phenytoin slow metabolizers

Clinical Neuropharmacology

Volumn 20, Issue 4, 1997, Pages 346-351

  Watanabe, Masao ^a   Iwahashi, Kazuhiko ^a   Kugoh, Toshiaki ^a   Suwaki, Hiroshi ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Michaelis Menten equation; Pharmacokinetics; Phenotyping; Phenytoin; Slow metabolizer

Indexed keywords

CARBAMAZEPINE; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; ASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; FEMALE; FOCAL EPILEPSY; HUMAN; JAPAN; MALE; MICHAELIS MENTEN KINETICS; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL;

EID: 0030755716     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199708000-00006     Document Type: Article

References (25)

1. Richens, A. A study of the pharmacokinetics of phenytoin (diphenylhydantoin) in epileptic patients, and the development of a nomogram for making dose increments. Epilepsia 1975;16:735-41.
2. Richens A. Clinical pharmacokinetics of phenytoin. Clin Pharmacol 1979;4:153-69.
3. Bauer LA, Blouin RA. Age and phenytoin kinetics in adult epileptics, Clin Pharmacol Ther 1982;31:301-4.
4. Grasela TH, Sheiner LB, Rambeck B, et al. Steady-state pharmacokinetics of phenytoin from routinely collected patient data. Clin Pharmacol 1983;9:355-64.
5. Hori R, Okumura K, Kitazawa S, et al. Estimation of population parameters in Japanese patients. III. Phenytoin. Yakuzaigaku 1990;50:292-9 (in Japanese).
6. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetie parameters. I. Michealis-Menten model. J Pharmacol Biopharmacol 1980;8:553-71.
7. Yukawa E, Higuchi S, Aoyama T. Population pharmacokinetics of phenytoin from routine clinical data in Japan. J Clin Pharmacol Ther 1989;14:71-7.
8. Kutt H, Wolk M, Scherman R, McDowell F. Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity. Neurology 1964;14:542-8.
9. Vasko MR, Bell RD, Daly DD, Pippenger CE. Inheritance of phenytoin hypometabolism : a kinetic study of one family. Clin Pharmacol Ther 1980;27:96-103.
10. Sloan TP. Idel J.R, Smith RL. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation. Clin Pharmacol Ther 1981;29:493-7.
11. DeWolff FA, Vermeij P, Ferrari MD, Buruma OJS, Breimer DD. Impairment of phenytoin parahydroxylation as a cause ot severe intoxication. Ther Drug Monit 1983;5:213-5.
12. Fritz S, Lindner W, Roots I, Frey BM, Küpfer A. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Ther 1987;241: 615-22.
13. 14C]-phenytoin in two healthy male volunteers. Can J Physiol Pharmacol 1983;61:403-7.
14. Steiner E, Iselius L, Alvan G, et al. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquine. Clin Pharmacol Ther 1987;38:394-401.
15. Inaba T. Phenytoin: pharmacogenetic polymorphism of 4′-hydroxylation. Pharmacol Ther 1990;46:341-7.
16. Niedermeyer E. Epilepsy guide. Diagnosis and treatment of epileptic seizure disorder. Baltimore and Münich: Urban and Schwarzenberg, 1983.
17. Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993: 3:61-70.
18. Kutt H, McDowell F. Management of epilepsy with diphenylhydantoin sodium. JAMA 1968;203:969-72.
19. Gonzalez FJ, Idel JR. Pharmacogenetic phenotyping and genotyping: present status and future potential. Clin Pharmacokinet 1994;26:59-70.
20. DeMorais SMF, Wilkinson GR, Blaisdell J, Mayer UA, Nakamura K, Goldstein JA. Identification of new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594 - 8.
21. Goldstein JA, DeMorais SMF. Biochemistry and molecular biology of the human CYP 2C subfamily. Pharmacogenetics 1944;4:285-99.
22. Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphism in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989;46:198-207.
23. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-8
24. Wilkinson GR, Guengerich FP, Branch RA. Genetic Polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;49:53-76.
25. Zielinski JJ, HaidukewYch D, Leheta BJ. Carbamazepine phenytoin interaction: Elevation of plasma phenytoin concentration due to carbamazepine comedication. Ther Drug Mnoit 1985;7:51-3.